Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Thoracic 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Gynecologic 1Gastrointestinal 1Dermatologic 1CNS 1Breast 1

Conditions

Breast Neoplasms 33Neoplasm Metastasis 7Ovarian Neoplasms 6Sarcoma 4Neoplasms 4Lymphoma, Non-Hodgkin 4Pancreatic Neoplasms 3Multiple Myeloma 3Lymphoma 3Glioma 3Endometrial Neoplasms 3Carcinoma, Renal Cell 3Wilms Tumor 2Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Neoplasms by Site 2Medulloblastoma 2Lymphoma, Mantle-Cell 2Lung Neoplasms 2Liposarcoma 2Leukemia, Myeloid, Acute 2Histiocytosis, Langerhans-Cell 2

Interventions

Magnetic Resonance Spectroscopy 56enzalutamide 44Specimen Handling 37apalutamide 35Androgen Antagonists 35Abiraterone Acetate 29Prednisone 27Radiosurgery 26darolutamide 25Docetaxel 23Pluvicto 22abiraterone 21Radiotherapy 21Leuprolide 20Biopsy 16relugolix 14acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 14gallium 68 PSMA-11 12Triptorelin Pamoate 12Surveys and Questionnaires 12Radiation 12Gonadotropin-Releasing Hormone 12X-Rays 112-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 10cabazitaxel 9bicalutamide 9Standard of Care 9Nivolumab 9Goserelin 9Carboplatin 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Prostatic Neoplasms × palbociclib × 90 days × Clear all
NCT02465060 2026-05-26

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT02905318 2026-03-09

Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer

Canadian Cancer Trials Group

Phase 2 Active not recruiting
19 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡